Andrew Penn, MS, PMHNP is a Clinical Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. He has practices as a psychiatric/mental health nurse practitioner, treating veterans and training residents at the San Francisco Veterans Administration Hospital.

As a researcher, he collaborates on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) lab at UCSF, serving as Co-PI on a phase 2 study of psilocybin for depression that was recently published in JAMA. He is currently working on a study using psilocybin to treat depression in patients with Parkinson’s disease and another examining psilocybin in the treatment of bipolar 2 depression.

A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses, advocating for the perspective of nurses in psychedelic therapy. He has published on psychedelics in the "Frontiers in Psychiatry," "Psychedelic Medicine," "The Journal of Humanistic Psychology" and "the American Journal of Nursing." An internationally invited speaker, he has lectured at SXSW, TEDx, Aspen Health Ideas Festival, the Singapore Ministry of Health, and Oxford University.

Nurses, Healthcare, Mental Health, Pharmaceutical, Health, Medicine Science,